MedTrace Logo

Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)

NCT00034853 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2013-11-01

No results posted yet for this study

Summary

To obtain safety, efficacy, pharmacokinetic and dosing information for meloxicam oral suspension in children with Juvenile Rheumatoid Arthritis (JRA)

Conditions

  • Arthritis, Juvenile Rheumatoid

Interventions

DRUG

meloxicam oral suspension

DRUG

naproxen oral suspension

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Purpose
TREATMENT
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-12-31
Primary Completion
2003-06-30

Countries

  • United States
  • Brazil
  • Mexico
  • Ukraine

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00034853 on ClinicalTrials.gov